Literature DB >> 30396567

Innovations in assisted reproductive technologies: impact on contemporary donor egg practice and future advances.

Mindy S Christianson1, José Bellver2.   

Abstract

Innovations in assisted reproductive technologies (ART) have driven progress in the donor egg field since the birth of the first baby derived from a donor egg in 1983. Over time, donor oocytes have become an increasingly used option for patients unable to conceive with autologous oocytes. In donor egg, the unique separation of the oocyte source and recipient uterus has created a model that has propelled advances in ART. Progressive ART innovations that have optimized the oocyte donor and resulting embryo include the following: evaluation of ovarian reserve, controlled ovarian hyperstimulation regimens that reduce the risk of ovarian hyperstimulation syndrome, blastocyst culture, oocyte cryopreservation, and preimplantation genetic testing. For donor egg recipients, methods to optimize the endometrium to maximize implantation include endometrial receptivity testing, immunologic donor-recipient matching, and increased understanding of the uterine microbiome.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Oocyte donation; assisted reproductive technology; donor egg

Mesh:

Year:  2018        PMID: 30396567     DOI: 10.1016/j.fertnstert.2018.09.020

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  2 in total

1.  Evaluation of the effect of intrauterine injection of platelet-rich plasma on the pregnancy rate of patients with a history of implantation failure in the in vitro fertilization cycle.

Authors:  Sara Ershadi; Narjes Noori; Alireza Dashipoor; Marzieh Ghasemi; Nahid Shamsa
Journal:  J Family Med Prim Care       Date:  2022-05-14

2.  The effect of lysophosphatidic acid-supplemented culture medium on human immature oocytes matured in vitro.

Authors:  Qigui Xie; Yaxin Xing; Jianhong Zhou; Ling Wang; Jie Wu; Ri-Cheng Chian
Journal:  Reprod Biol Endocrinol       Date:  2021-06-04       Impact factor: 5.211

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.